Top-News
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into the Fairness of the Acquisition of Amedisys, Inc. by Option Care Health, Inc.
NEW YORK, June 29, 2023 /PRNewswire/ -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All Persons or Entities who purchased Amedisys, Inc. ("Amedisys" or the "Company") (NASDAQ: AMED) stock prior to May 3, 2023.
You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of Amedisys by Option Care Health, Inc. ("Option Care"). As a result of the merger, Amedisys stockholders are anticipated to receive only 3.0213 shares of Option Care common stock, at the time indicating a value of $97.38 per share. On June 5, 2023, UnitedHealth Group made an offer to purchase Amedisys for $100.00 per share in cash, but the Company's agreement with Option Care limits the Board's ability to accept this new offer.
To learn more about the action and your rights, go to:
or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500. There is no cost or obligation to you.
The Amedisys merger investigation concerns whether the Board of Amedisys has harmed stockholders by agreeing to enter into the transaction with Option Care and whether all material facts have been properly disclosed to stockholders.
Levi & Korsinsky is a nationally recognized firm with offices in New York, Connecticut, California, and Washington, D.C. The firm's attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities lawsuits and have recovered hundreds of millions of dollars for aggrieved shareholders. For more information, please feel free to contact any of the attorneys listed below. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/shareholder-alert-levi--korsinsky-llp-notifies-investors-of-an-investigation-into-the-fairness-of-the-acquisition-of-amedisys-inc-by-option-care-health-inc-301867207.html
SOURCE Levi & Korsinsky, LLP
Für dich aus unserer Redaktion zusammengestellt
Community-Beiträge zu Amedisys
16.04.2020 - 18:55 Uhr
Tamakoschy Q2
https://www.marketscreener.com/AMEDISYS-INC-8342/news/Amedisys-4Q-Earnings-Snapshot-30015348/
Amedisys: 4Q Earnings Snapshot
share with twitter share with LinkedIn share with facebook share via e-mail
0
02/18/2020 | 10:36pm BST
BATON ROUGE, La. (AP) _ Amedisys Inc. (AMED) on Tuesday reported fourth-quarter earnings of $27.7 million.
The Baton Rouge, Louisiana-based company said it had profit of 83 cents per share. Earnings, adjusted for non-recurring costs, were 94 cents per share.
The results exceeded Wall Street expectations. The average estimate of eight analysts surveyed by Zacks Investment Research was for earnings of 93 cents per share.
The home health care and hospice services provider posted revenue of $500.7 million in the period, falling short of Street forecasts. Seven analysts surveyed by Zacks expected $510.4 million.
For the year, the company reported profit of $126.8 million, or $3.84 per share. Revenue was reported as $1.96 billion.
Amedisys expects full-year earnings in the range of $4.90 to $5.13 per share, with revenue in the range of $2.12 billion to $2.16 billion.
Amedisys shares have risen 21% since the beginning of the year. In the final minutes of trading on Tuesday, shares hit $202.02, an increase of 48% in the last 12 months.
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on AMED at https://www.zacks.com/ap/AMED
16.09.2010 - 22:17 Uhr
martin30sm die Kursentwicklung der letzten Tage
sieht gut aus....
Jetzt anmelden und diskutieren
Registrieren
Login
Zum Thread wechseln
Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte.
